NCT04855825

Brief Summary

The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. The study will evaluate the mobility, learning and memory, and walking abilities of individuals with multiple sclerosis who went through the traditional as compared to others who used the robotic exoskeleton as part of their therapy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable multiple-sclerosis

Timeline
21mo left

Started Oct 2017

Longer than P75 for not_applicable multiple-sclerosis

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Oct 2017Dec 2027

Study Start

First participant enrolled

October 5, 2017

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 18, 2018

Completed
2.8 years until next milestone

First Posted

Study publicly available on registry

April 22, 2021

Completed
6.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2027

Last Updated

November 24, 2025

Status Verified

November 1, 2025

Enrollment Period

10.2 years

First QC Date

June 18, 2018

Last Update Submit

November 19, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Distance walked in a specific time duration

    The distance walked (meters) in 6 minutes is measured. This is following the 6-minute walk test (6MWT) procedure to measure walking endurance. The 6MWT is is a valid and reliable test of endurance walking performance in persons with MS. Participants are instructed to walk as fast and as far as possible for 6 minutes within a single corridor and performing 180° turns.

    approximately 12 weeks

  • Neuropsychological measures of thinking

    Processing speed and cognition outcomes, including: The Symbol Digit Modalities Test (SDMT) represents the primary CPS outcome in the current proposal. This test involves the conversion of a set of simple geometric designs into an oral response. It has been demonstrated to be sensitive to the presence of brain damage in numerous studies. The SDMT requires the examinee to substitute a number for a randomized presentation of a geometric figure. The appropriate number is shown in a key containing the Arabic numbers 1 through 9, each paired with a different geometric figure. The total number of correct responses in 90 seconds is the primary outcome of the SDMT.

    approximately 12 weeks

  • Brain scans

    Participants will undergo neuroimaging scans of the brain to acquire structural imaging of the brain using Magnetic resonance imaging (MRI). The MRI instrument that will be used is an FDA-approved Siemens Skyra 3T clinical imager housed in the Rocco Ortenzio Neuroimaging Center at Kessler Foundation.

    approximately 12 weeks

Study Arms (2)

Robotic Exoskeleton Therapy

EXPERIMENTAL

Gait rehabilitation provided using a wearable robotic exoskeleton

Device: Robotic Exoskeleton Rehabilitation

Conventional Gait Therapy

ACTIVE COMPARATOR

Gait rehabilitation provided using traditional gait therapy under the supervision of a licensed PT

Other: Conventional Gait Therapy

Interventions

Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.

Robotic Exoskeleton Therapy

Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.

Conventional Gait Therapy

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Be diagnosed with multiple sclerosis.
  • Be determined by the study staff to have moderate to severe difficulty walking but still be able to walk while using the robotic exoskeleton.
  • Have some difficulty thinking and problem solving as determined by my performance on a special test that I will take during the screening visit.
  • Be between the ages of 18 and 75.
  • Be free from flair ups of my MS Symptoms for at least one month prior to testing.
  • Discuss with study staff how to maintain a constant level of my spasticity medication (for example baclofen) throughout the study.
  • Be able to walk (with the use of one or more assistive device if needed).
  • Have English as my primary language.
  • Be able to physically fit into the exoskeleton device: height between 60 and 76", weight under 220 lbs.
  • Be able to tolerate upright standing for 30 minutes with assistance if needed.
  • Have normal joint range of motion for walking as determined by study staff.
  • Have sufficient strength to use the hemiwalker, bilateral canes or walker while wearing the RE.
  • Have stable blood pressure.
  • Be willing and able to give informed consent.
  • Be able and willing to comply with study procedures and follow directions and commands, verbal instructions, and follow-up requirements.

You may not qualify if:

  • Have a history of head injury, stroke, seizures, or any other significant neurological history other than MS.
  • Have a high degree of difficulty in thinking and problem solving that prevents me from participating in the study as determined by my performance on a special test taken during the screening visit.
  • Be currently taking steroids, benzodiazepines, antipsychotics, and/or neuroleptics as determined by study staff review of my medications.
  • Be pregnant.
  • Be completely reliant on a wheelchair.
  • Have joint contracture or spasticity of any limb that limits normal range of motion during walking with assistive devices as determined by study staff.
  • Have skin issues that would prevent wearing the RE.
  • Have pressure sore stage 2 or higher located in an area that would negatively affect weight bearing, harness fit, or therapist assistance.
  • Have orthopedic issues or history that will interfere with walking or limit the range of motion of the lower limbs (e.g., knee replacement, inflammation)
  • Have been hospitalized for heart attack, heart surgery or acute heart failure within 3 months of enrollment in study.
  • Have any other medical conditions that my doctor or physical therapist feels would affect my ability to use the robotic device.
  • Have a pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments.
  • Have dental implants- I should discuss any dental implants with the investigators.
  • Have been told by my doctor that it is unsafe for me to have a regular MRI as part of my medical care.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kessler Foundation

West Orange, New Jersey, 07052, United States

RECRUITING

MeSH Terms

Conditions

Multiple SclerosisGait Disorders, NeurologicCognitive Dysfunction

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsCognition DisordersNeurocognitive DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Director

Study Record Dates

First Submitted

June 18, 2018

First Posted

April 22, 2021

Study Start

October 5, 2017

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2027

Last Updated

November 24, 2025

Record last verified: 2025-11

Locations